University of Crete (UOC)
Ινωτικές διάμεσες πνευμονοπάθειες και διαταραχές της αναπνοής κατά τον ύπνο
Abstract
dc:descriptionIdiopathic Pulmonary Fibrosis (IPF) represents a specific form of Interstitial lung Diseases (ILDs) of unknown cause, with a fatal prognosis. Although IPF is limited to the lungs, many comorbid conditions may influence the prognosis and modify the natural course of the disease. Importantly, sleep-related disorders, such as obstructive sleep apnoea (OSA) have been recognized as an important comorbidity in the latest official guidelines for the diagnosis and management of IPF1. Moreover, the prevalence of OSA on IPF has been reported from 50% to 90%, higher than in the general population. Most of these patients have moderate to severe OSA [apnea-hypopnea index (AHI) >15 events per hour]. It is worth noting that the presence of OSA in IPF patients has been associated with worse prognosis in terms of mortality and clinical deterioration6. In addition, severe OSA was strongly associated with ischemic heart disease in newly diagnosed IPF patients compared to patients with no or mild-to-moderate OSA. Despite these adverse clinical outcomes few IPF patients are evaluated for OSA. As with the general population, moderate-to-severe OSA in IPF patients should be treated with positive airway pressure (PAP), which has been shown to improve quality of life and sleep. However, PAP non-adherence is common due to a variety of reasons such as claustrophobia, irritating cough during sleep, insomnia, and depression. Previously we have shown that PAP therapy reduced mortality and resulted in significant improvement in all used quality-of-life and sleep instruments in treatment-naïve IPF patient after one year’s effective PAP treatment. However, new prospective clinical trials are needed in the long term about the impact of this treatment in the prognosis of the disease. Study Objectives: Obstructive sleep apnea (OSA) in patients with idiopathic pulmonary fibrosis (IPF) is associated with worse mortality and clinical outcome. We aimed to assess differences between patients with IPF with and without OSA and the effect of positive airway pressure treatment on sleep and overall life quality, morbidity, and mortality in these patients.Methods: Forty-five patients with newly diagnosed IPF underwent polysomnography. Using an apnea-hypopnea index ≥ 15 events/h for OSA diagnosis resulted in 16 patients with IPF and 29 with IPF-OSA. The patients completed the Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcomes in Sleep Questionnaire, Fatigue Severity Scale, Short Form-36 life questionnaire, and Beck Depression Inventory before and at the end of the follow-up period. Results: Patients with IPF-OSA showed the most severe functional impairments in questionnaires, especially for General Health component of the Short Form-36 life questionnaire (37 vs 58, P = .03). At the 7-year follow-up, 16 (36%) patients had died, 6 (38%) in the IPF group and 10 (35%) in IPF-OSA group. Patients with ≥6-hour positive airway pressure use had better survival compared with patients with <6-hour use (P = .04). Significant improvement was also observed in Epworth Sleepiness Scale (3 vs 6, P =.03), Pittsburgh Sleep Quality Index (5 vs 8, P =.01), and Fatigue Severity Scale (37 vs 48, P =.008) score in patients with ≥4-hour positive airway pressure use. Conclusions: OSA plays a significant role on clinical features and quality of life in patients with IPF. Effective positive airway pressure treatment results in a significant improvement in sleepiness, fatigue, sleep quality, and mortality.Study Impact: Our results show that management of obstructive sleep apnea in idiopathic pulmonary fibrosis is important because of its significant impact in life expectancy and quality of life. These findings underline the importance of comorbid obstructive sleep apnea awareness and effective treatment in patients with idiopathic pulmonary fibrosis.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papadogiannis, Georgios
- Παπαδογιάννης, Γεώργιος
Subjects
dc:subject × 17Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52925